Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences
Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous administration compared with previously developed rapid-acting insulins. The pharmacokinet...
Guardado en:
Autores principales: | Hanne Haahr, Tim Heise |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8f6ea16d2b274e568069cac42f9f1865 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study
por: Yi Tao, et al.
Publicado: (2021) -
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
por: Vadim Valer'evich Klimontov, et al.
Publicado: (2014) -
Assessment the equivalence of the bioanalogue insulin lizpro biphasic 25 (Geropharm-bio, Russia) and Humalog® Mix 25 (Lilly France, France) using the euglycemic hyperinsulinum clamp method on healthy volonters
por: Alexander Y. Mayorov, et al.
Publicado: (2018) -
Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice
por: Roganović Maša, et al.
Publicado: (2021) -
The impact of “faster aspart” on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump
por: Jesús González de Buitrago Amigo, et al.
Publicado: (2021)